Annual Report And Accounts

Overview

The report describes the company's advancement of inhaled interferon beta into the clinic, completion of Part 1 of SG015 and progress in Part 2, including 13 UK sites. It also highlights the £2.7 million October 2018 fundraising to expand the trial, while reporting 2018 revenue of £0.11 million.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2018
Period: Ends 31 December 2018
Publication date: 22 February 2019
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services